Biotek-snakken — Juli 2023
-
2023-07-13 17:33
Andreas Norlin har den 13 juli köpt 5 939 aktier i forskningsbolaget Ascelia Pharma där han är forskningschef. Aktierna köptes till kursen 14,50 kronor per aktie, en affär på 86 100 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.Nyhetsbyrån Finwire
-
July 17, 2023 at 8:00:00 AM: "Saniona enters into collaboration agreement with AstronauTx in Alzheimer’s disease"
-
New Alzheimer’s Drug Is First to Show It Slows Disease. But It’s Facing a Rocky Rollout https://firstwordpharma.com/story/5761407
-
Godt at høre lidt positivt nyt fra Saniona.. går stille og roligt den rigtige vej. Min tilgang til denne har hele tiden været deres platform, så selvom de ikke lykkes med at køre produkter hele vejen igennem, er der stor værdi at hente for dem, i udviklingen af aktive stoffer for andre..
-
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In. https://firstwordpharma.com/story/5761397
-
Acumen Pharma Reports Positive Trial Results Of ACU193 In Early Alzheimer's Disease https://www.proinvestor.com/investornyt/1015998/acumen-pharma-reports-positive-trial-results-of-acu193-in-early-alzheimers-disease
-
Alnylam Presents ALN-APP's Updated Positive Interim Phase 1 Results In Alzheimer's Disease, CAA https://www.proinvestor.com/investornyt/1015996/alnylam-presents-aln-apps-updated-positive-interim-phase-1-results-in-alzheimers-disease-caa
-
Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What To Expect
17/7 10:18
In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. https://www.proinvestor.com/investornyt/1016000/acadia-pharmaceuticals-rights-deal-and-bullish-outlook-sends-shares-surging-16-heres-what-to-expect
-
Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?
https://www.proinvestor.com/investornyt/1015999/acadia-acad-soars-247-is-further-upside-left-in-the-stock -
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications - Recludix Pharma
– Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales –– Recludix to lead research and development until start of Phase 2 –– Recludix has an option to participate equally in U.S. profit/loss sharing – SAN DIEGO, CA, July […]
Recludix Pharma (recludixpharma.com)
-
RAPT Therapeutics er faldet lidt tilbage efter de blev forsinket et halvt år med deres fase IIb studie i AD med RAPT193. De er dog ved at inkludere flere sites, så måske henter de lidt af tiden ind igen. Hvis data munder godt ud, så er det planen at gå efter en licensaftale - og den skulle gerne blive ganske fornuftigt. Da de ikke har ret meget andet i pipelinen, så kunne man måske også se et salg af hele selskabet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind